Non-exec buys after Smiths rejects approach for division
A round-up of the biggest director deals today so far.
Bruno Angelici, a non-executive director of Smiths Group, has bought his first shares in the company less than a week after it was revealed that the technology supplier had rejected an approach for its medical division.
Angelici paid 1392p a share for the 2,000 shares he acquired - a total outlay of nearly £28,000. The share price closed at 1283p on 13 January - the day before the approach was revealed.
Angelici joined the Smiths board in July 2010. The French man is a former executive of AstraZeneca and he was received into the Legion d'honneur in December 2009.
Subscribe to MoneyWeek
Subscribe to MoneyWeek today and get your first six magazine issues absolutely FREE
Sign up to Money Morning
Don't miss the latest investment and personal finances news, market analysis, plus money-saving tips with our free twice-daily newsletter
Don't miss the latest investment and personal finances news, market analysis, plus money-saving tips with our free twice-daily newsletter
Smiths rejected a £2.45bn approach for its biggest division Smiths Medical. It said it had carefully considered the approach, which came from the private equity group Apax according to media reports, concluding that continuing discussions on the basis of a sale at that level would not be in shareholders' best interests.
Smiths Medical accounted for about 31% of the company's sales last year.
Research company Edison Investment, however, expects Smiths to be broken up at some point. "We feel that it is only a matter of time before a satisfactory bid will kick-start the process," Edison said.
Smiths is expected to announce its interim results on 23 March.
Top Director Buys
Smiths Group (SMIN) Director name: Mr Bruno AngeliciAmount purchased: 2,000 @ 1,392.00p Value: £27,840
Midas Income & Growth Trust (MIGT) Director name: Mr Hubert ReidAmount purchased: 18,868 @ 116.50p Value: £21,981
ViCTory VCT (VICT) Director name: Mr Christopher MoorsomAmount purchased: 43,000 @ 38.00p Value: £16,340
Elektron (EKT) Director name: Mr Jeremy Gordon ThornAmount purchased: 38,000 @ 40.60p Value: £15,428
Elektron (EKT) Director name: Mr Jeremy Gordon ThornAmount purchased: 38,000 @ 40.60p Value: £15,428
ViCTory VCT (VICT) Director name: Mr David M PageAmount purchased: 32,620 @ 38.00p Value: £12,396
Top Director Sells
Cairn Energy (CNE) Director name: Mr Malcolm ThomsAmount sold: 212,300 @ 448.09p Value: £951,295
Cairn Energy (CNE) Director name: Mr Philip TracyAmount sold: 141,534 @ 448.09p Value: £634,200
Alternative Networks (AN.) Director name: Mr Edward SpurrierAmount sold: 300,000 @ 190.00p Value: £570,000
Cairn Energy (CNE) Director name: Sir Bill GammellAmount sold: 116,371 @ 448.09p Value: £521,447
Alternative Networks (AN.) Director name: Mr James MurrayAmount sold: 250,000 @ 190.00p Value: £475,000
Bankers Petroleum Ltd. (BNK) Director name: Mr Eric M BrownAmount sold: 50,000 @ 552.47p Value: £276,235
Alternative Networks (AN.) Director name: Mr Benjamin MarnhamAmount sold: 225,000 @ 190.00p Value: £427,500
Next (NXT) Director name: Mr C E AngelidesAmount sold: 18,953 @ 2,148.00p Value: £407,110
Cairn Energy (CNE) Director name: Dr Mike J WattsAmount sold: 82,561 @ 448.09p Value: £369,948
Sign up for MoneyWeek's newsletters
Get the latest financial news, insights and expert analysis from our award-winning MoneyWeek team, to help you understand what really matters when it comes to your finances.
-
What happens if you can’t pay your tax bill, and what is "Time to Pay"?
Millions are due to file their tax return this Friday as the self-assessment deadline closes. Though the nightmare is not over until you pay the taxman what you owe - or face a penalty. But what happens if you can't afford to pay HMRC your tax bill, and what is "Time to Pay"?
By Kalpana Fitzpatrick Published
-
What does Rachel Reeves’s plan for growth mean for UK investors?
Rachel Reeves says she is going “further and faster” to kickstart the UK economy, but investors are unlikely to be persuaded
By Katie Williams Published